Startseite Kongressberichte & Archiv 59th ASH Annual Meeting and Exposition Press Conferences Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies

Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies

 

Webcasts at the bottom (videos by courtesy of VJHemOnc)

Abstracts: 

578 Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, et al. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Slides (By courtesy of Sattva S. Neelapu)

The authors of this study conclude that:

In the ZUMA-1 study, axi-cel demonstrated significant clinical benefit with manageable AEs in patients with no curative treatment options. Additional long-term efficacy, safety, subgroup, and biomarker associative analyses with a median of 15 months of follow-up will be presented. Loss of CD19 and gain of PD-L1 expression in tumors are identified as possible mechanisms of resistance following axi-cel treatment. These results provide insights into development of novel therapeutic strategies to overcome CD19 CAR T resistance and further improve outcomes in these patients.

 

See also the article which appeared simultaneously in the NEJM:

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, M.D., Frederick L. Locke, M.D., Nancy L. Bartlett, M.D., Lazaros J. Lekakis, et al.

 

577 Stephen J. Schuster, Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, et al. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The authors of this study conclude that:

CTL019 produces high response rates with 95% of CRs at 3 months being sustained at 6 months in a cohort of highly pretreated adult patients with r/r DLBCL, results which confirm the findings of our earlier interim analysis. Centralized manufacturing was feasible in the first global study of CAR T cell therapy in DLBCL. CRS and other AEs could be effectively and reproducibly managed by appropriately trained investigators without treatment-related mortality.

 

 

See also the article which appeared simultaneously in the NEJM:

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas Stephen J. Schuster, M.D., Jakub Svoboda, M.D., Elise A. Chong, M.D., Sunita D. Nasta, M.D., et al. 

 

740 Jesus G. Berdeja, Yi Lin, Noopur Raje, Nikhil Munshi, et al.and James N. Kochenderfer, MD Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

The authors of this study conclude that:

bb2121 shows promising efficacy at dose levels above 50 x 106 CAR+ T cells, with manageable CRS and no DLTs to date. ORR was 100% at these dose levels with 8 ongoing clinical responses at 6 months and 1 patient demonstrating a sustained response beyond one year. These initial data support the potential of CAR T therapy with bb2121 as a new treatment paradigm in RRMM. Slides (By courtesy of James N. Kochenderfer